Felbatol, also known as Felbamate, is indicated for the control of certain epileptic seizures in adults and a rare form of epilepsy in children known as Lennox-Gastaut Syndrome. About two million people in the United States are affected by epilepsy, a disorder characterized by seizures. Seizures occur when nerves in the brain fire spontaneously, causing symptoms ranging from shaking of a single arm or leg to loss of consciousness and generalized spasms. In many cases, seizures cannot be adequately controlled with currently available medications.
The most common side effects of felbamate include
and nervous system complaints, such as dizziness
and vomiting, and abdominal pain. The labeling recommends that when it is used with other antiepilepsy drugs, doctors should
adjust doses of the other drugs in order to decrease the likelihood of side effects. Felbatol is also linked to hepatic failureIn 1994, the U.S. Food and Drug Administration (FDA) recommended the immediate withdrawal of patients from Felbatol because of its link to several cases of aplastic anemia. Aplastic anemia is a rare and frequently fatal form of bone
marrow failure. The rate of aplastic anemia cases reported with Felbatol was about 50 times higher than expected.
Felbatol was approved by the FDA in 1993 and is manufactured by Wallace Laboratories of
See your doctor if you have experienced serious side effects associated with Felbatol. In addition, it may be important to contact an attorney
who can help you protect your legal rights. Please keep in mind that there may be time limits
within which you must commence suit.
- Epilepsy Drugs: Overview
- Balance Problems: Overview
- Digestive Disorders: Overview
- Head, Spinal Cord, Brain & Nerve Disorders: Overview
- Liver Failure: Overview